Sionna Therapeutics, Inc. Common Stock
SIONStock
$45.29+139.50%52W
Market Cap$2.00B
P/E—
Div yield—
Beta1.50
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-6.75%
Price vs S&P 500 (4W)27.12%
VGM Score68.86
Market Capitalization$2.00B
Earnings Surprise History
Q1 26-0.60est. -0.52
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.19
4.19
4.19
4.18
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SIONSionna Therapeutics, Inc. Common Stock | — | — | B | $45.29 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for cystic fibrosis (CF), a progressive genetic disorder caused by mutations in the CFTR gene. The company's approach targets the disease mechanism by normalizing CFTR protein function to deliver clinically meaningful benefits. The company is entirely focused on CF drug development.